Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now later-stage tilt small index

Primary Biliary Cholangitis: later-stage trial registry

4 of 9 indexed Primary Biliary Cholangitis trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Primary Biliary Cholangitis: 9 US clinical trials tracked, 4 recruiting.

Primary Biliary Cholangitis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 3 of these trials.

Enrollment posture brief

Registry condition primary-biliary-cholangitis

OPEN 4 | RECR 44% | LATE 5 | EARLY 2 | RANK #1916 | SPON 3

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Primary Biliary Cholangi (th…44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Primary Biliary Cholangitis

Primary Biliary Cholangitis lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Biliary Cholangitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Biliary Cholangitis is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Primary Biliary Cholangitis research.

    Gilead Sciences accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Primary Biliary Cholangitis enrolment sits around 150 participants.

    Median target enrolment is 150 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.

  4. Primary Biliary Cholangitis research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 35

Open and recent trials

9 total, page 1 of 1

RECRUITING 424 participants

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Ipsen

NCT06447168

RECRUITING Phase 3 318 participants

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Gilead Sciences

NCT06051617

RECRUITING Phase 2 260 participants

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Mirum Pharmaceuticals

NCT05050136

RECRUITING Phase 3 150 participants

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Zydus Therapeutics

NCT06427395

ACTIVE NOT RECRUITING Phase 3 90 participants

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Gilead Sciences

NCT06060665

ACTIVE NOT RECRUITING Phase 3 69 participants

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Ipsen

NCT06383403

ACTIVE NOT RECRUITING Phase 2 46 participants

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Kowa Research Institute

NCT06247735

ACTIVE NOT RECRUITING 30 participants

A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)

Ipsen

NCT07049887

COMPLETED Phase 3 265 participants

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Gilead Sciences

NCT03602560

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 5

Top Sponsors

Named interventions

Most-linked intervention names on Primary Biliary Cholangitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
seladelpar 10 mg Drug
1 trials
seladelpar 5-10 mg Drug
1 trials
Seladelpar 10 mg Drug
1 trials
K-808 (Dose B) Drug
1 trials
K-808 (Dose A) Drug
1 trials
Seladelpar Drug
1 trials
Elafibranor Drug
1 trials

US sites by state

Facility locations filed on Primary Biliary Cholangitis trials. A trial with sites in several states counts in each.

Florida 9 trials
California 8 trials
Colorado 7 trials
Texas 5 trials
Louisiana 5 trials
Illinois 5 trials
Georgia 5 trials
Arizona 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Biliary Cholangitis page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Primary Biliary Cholangitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Gilead Sciences sponsors the most Primary Biliary Cholangitis trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Biliary Cholangitis condition card totals 9 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.